NewAmsterdam Pharma Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
100
- Stock Symbol
-
NAMS
- Investments
-
3
- Share Price
-
$20.14
- (As of Friday Closing)
NewAmsterdam Pharma General Information
Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Contact Information
Website
www.newamsterdampharma.comCorporate Office
- 20803 Biscayne Boulevard
- Suite 105
- Aventura, FL 33180
- United States
Corporate Office
- 20803 Biscayne Boulevard
- Suite 105
- Aventura, FL 33180
- United States
NewAmsterdam Pharma Timeline
NewAmsterdam Pharma Stock Performance
As of 13-Nov-2026, NewAmsterdam Pharma’s stock price is $20.14. Its current market cap is $2.42B with 120M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.14 | $19.97 | $17.90 - $42.20 | $2.42B | 120M | 1.58M | -$1.69 |
NewAmsterdam Pharma Financials Summary
As of 30-Sep-2026, NewAmsterdam Pharma has a trailing 12-month revenue of $25.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,273,372 | 3,275,069 | 2,329,045 | 502,896 |
| Revenue | 25,937 | 22,503 | 45,563 | 14,090 |
| EBITDA | (226,554) | (231,191) | (258,367) | (188,144) |
| Net Income | (204,888) | (203,819) | (241,598) | (176,937) |
| Total Assets | 687,985 | 769,284 | 864,620 | 347,097 |
| Total Debt | 76 | 202 | 448 | 60 |
NewAmsterdam Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NewAmsterdam Pharma Comparisons
Industry
Financing
Details
NewAmsterdam Pharma Competitors (98)
One of NewAmsterdam Pharma’s 98 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Formerly VC-backed | Tuebingen, Germany | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Histogen | Formerly VC-backed | San Ramon, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
NewAmsterdam Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NewAmsterdam Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NewAmsterdam Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NewAmsterdam Pharma Investments & Acquisitions (3)
NewAmsterdam Pharma’s most recent deal was a Merger/Acquisition with Frazier Lifesciences Acquisition. The deal was made on 25-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Frazier Lifesciences Acquisition | 25-Jul-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Amgen (Obicetrapib) | 09-Apr-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Dezima Pharma | 01-Apr-2020 | Merger/Acquisition | Drug Discovery |
NewAmsterdam Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
NewAmsterdam Pharma FAQs
-
When was NewAmsterdam Pharma founded?
NewAmsterdam Pharma was founded in 2019.
-
Where is NewAmsterdam Pharma headquartered?
NewAmsterdam Pharma is headquartered in Aventura, FL.
-
What is the size of NewAmsterdam Pharma?
NewAmsterdam Pharma has 100 total employees.
-
What industry is NewAmsterdam Pharma in?
NewAmsterdam Pharma’s primary industry is Drug Discovery.
-
Is NewAmsterdam Pharma a private or public company?
NewAmsterdam Pharma is a Public company.
-
What is NewAmsterdam Pharma’s stock symbol?
The ticker symbol for NewAmsterdam Pharma is NAMS.
-
What is the current stock price of NewAmsterdam Pharma?
As of 13-Nov-2026 the stock price of NewAmsterdam Pharma is $20.14.
-
What is the current market cap of NewAmsterdam Pharma?
The current market capitalization of NewAmsterdam Pharma is $2.42B.
-
What is NewAmsterdam Pharma’s current revenue?
The trailing twelve month revenue for NewAmsterdam Pharma is $25.9M.
-
Who are NewAmsterdam Pharma’s competitors?
Immatics, Rein Therapeutics, Arvinas, Histogen, and Sarepta Therapeutics are some of the 98 competitors of NewAmsterdam Pharma.
-
What is NewAmsterdam Pharma’s annual earnings per share (EPS)?
NewAmsterdam Pharma’s EPS for 12 months was -$1.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
